» Articles » PMID: 31348749

Transplanting Kidneys from Donors with Small Renal Masses - a Strategy to Expand the Donor Pool

Overview
Specialty Urology
Date 2019 Jul 27
PMID 31348749
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Renal transplantation is the optimal treatment for end-stage renal disease, but organ demand continues to outstrip supply. The transplantation of kidneys from donors with small renal masses (SRMs) represents a potential avenue to expand the donor pool. We reviewed all published cases of transplants from donors with SRMs and we present followup data, best practices, and outline an actionable series of steps to guide the implementation of such transplants at individual centers.

Methods: A detailed literature search of the MEDLINE/PubMed and SCOPUS databases was performed. Thirty unique data sets met inclusion criteria and described the transplantation of tumor-ectomized kidneys; nine data sets described the transplantation of contralateral kidneys from donors with SRMs.

Results: A total of 147 tumorectomized kidneys have been transplanted. Pathology revealed 120 to be renal cell carcinomas (RCCs), of which 116 were stage T1a (0.3-4 cm). The mean followup time was 44.2 months (1-200). A single suspected tumor recurrence occurred in one patient nine years post-transplantation and it was managed with active surveillance. Twenty-seven kidneys have been transplanted from deceased donors with contralateral renal masses. Pathology revealed 25 to be RCCs, of which 19 were confirmed to be stage T1 (<7 cm). The mean followup time was 46.7 months (0.5-155). One recipient developed an RCC and underwent curative allograft nephrectomy.

Conclusions: Careful use of kidneys from donors with SRMs is feasible and safe, with an overall recurrence rate of less than 1.5%. The use of such kidneys could help alleviate the organ shortage crisis.

Citing Articles

Optimizing the kidney donor pool: transplanting donor kidneys after partial nephrectomy of masses or cysts.

Tabbara M, Riella J, Gonzalez J, Gaynor J, Guerra G, Alvarez A Front Surg. 2024; 11:1391971.

PMID: 38726469 PMC: 11080618. DOI: 10.3389/fsurg.2024.1391971.


Redefining the urologist's role in kidney transplantation.

Branchereau J World J Urol. 2020; 40(1):301-302.

PMID: 33175209 DOI: 10.1007/s00345-020-03520-5.


The history of renal transplantation in Canada: A urologic perspective.

Levine M, Chin J, Rasmussen A, Sener A, Luke P Can Urol Assoc J. 2020; 14(12):372-379.

PMID: 32569569 PMC: 7704082. DOI: 10.5489/cuaj.6744.

References
1.
Carver B, Zibari G, Venable D, Eastham J . Renal cell carcinoma detected in a cadaveric donor after orthotopic liver and contralateral renal transplantation in two recipients: four-year follow-up. Transplantation. 2001; 71(9):1348-9. DOI: 10.1097/00007890-200105150-00031. View

2.
Donat S, Diaz M, Bishoff J, Coleman J, Dahm P, Derweesh I . Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol. 2013; 190(2):407-16. DOI: 10.1016/j.juro.2013.04.121. View

3.
McGregor T, Rampersad C, Patel P . Expanding living kidney donor criteria with ex-vivo surgery for renal anomalies. Can Urol Assoc J. 2016; 10(9-10):301-305. PMC: 5085905. DOI: 10.5489/cuaj.3841. View

4.
MacLennan S, Imamura M, Lapitan M, Omar M, Lam T, Hilvano-Cabungcal A . Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol. 2012; 62(6):1097-117. DOI: 10.1016/j.eururo.2012.07.028. View

5.
Hetet J, Rigaud J, Blancho G, Renaudin K, Bouchot O, Karam G . [Renal transplantation after excision of an angiomyolipoma on living donor kidney]. Prog Urol. 2004; 14(2):205-6. View